

FROM: Cornerstone Pharmaceuticals, Inc.
1 Duncan Drive
Cranbury, NJ 08512
info@cornerstonepharma.com

Rubenstein Public Relations
Contact: Adam Mazur
(212) 843-8073 / amazur@rubensteinpr.com

FOR IMMEDIATE RELEASE

CORNERSTONE PHARMACEUTICALS ADDS NEW CLINICAL TRIAL SITE FOR THE EVALUATION OF ITS FIRST IN CLASS ANTI-CANCER AGENT CPI-613

CRANBURY, NJ, February 8, 2010 – Cornerstone Pharmaceuticals, Inc. (<http://www.cornerstonepharma.com>), the private pharmaceutical company behind experimental cancer drug CPI-613 - with multiple ongoing phase I/II clinical trials - has announced it has added Pivotal Research Centers (www.pivotalresearch.com), operators of several medical research facilities in the western U.S., to its roster of clinical trial sites for its single agent phase I/II clinical trial at Pivotal's Peoria, Arizona location.

"This is a very significant development for our Company as we expand the clinical trials of CPI-613 and continue to partner with institutions that share our vision of helping people to better manage their affliction," commented Dr. Robert Shorr, CEO for Cornerstone Pharmaceuticals. "I welcome Pivotal Research Centers to the Cornerstone network."

Divis Khaira, MD, Clinical Trial Investigator for Pivotal Research Center said, "We are very pleased to join together with Cornerstone as a test site location and share their core mission to endeavor to bring CPI-613 through its development and ultimately to those in need to make various cancers more manageable and perhaps even treatable."

CPI-613 is the initial candidate to emerge from Cornerstone's Altered Energy Metabolism Directed (AEMD) technology platform. CPI-613 is the first drug in a new

chemical class that, through a novel mechanism, targets metabolic changes that may be common to many cancer types. CPI-613 has been granted orphan drug status by the US FDA for pancreatic cancer, a cancer type that typically has a poor prognosis, spreads rapidly and often goes undetected in its early stages.

About Pivotal Research Centers

Pivotal Research Centers specializes in high quality clinical research. It is staffed by medical professionals who understand and care about the people who volunteer for the clinical studies. Our personnel are experts in their fields and have a commitment to conducting the clinical trials in a relaxed and pleasant setting.

Pivotal Research Centers was established in 1993 and has grown into three locations; two sites in the Phoenix Metropolitan area (Peoria /Sun City and Mesa), and a site in the Metropolitan area of Salt Lake City. For further information call 1-866-STUDY 21 / 1-866-788-3921 or visit www.pivotalresearch.com.

About Cornerstone Pharmaceuticals

Cornerstone Pharmaceuticals, Inc. is a privately held pharmaceutical company singularly focused on the discovery and development of innovative cancer therapies that exploit the metabolic pathways that are common to different cancer types but different from normal cells and tissues. This unique approach, i.e. understanding and addressing what is similar to multiple cancer types rather than the differences between each, offers a significant opportunity to make a profound impact on the clinical treatment of a variety of cancers.

Cornerstone's AEMD technology platform was established on cancer metabolism research performed in the laboratories of Paul M. Bingham, Ph.D. and Zuzana Zachar, Ph.D., at the State University of New York at Stony Brook, Stony Brook, NY.

Cornerstone has offices and laboratory facilities in both Cranbury, NJ. and Stony Brook, NY. For further information, visit <http://www.cornerstonepharma.com>. To arrange an interview with Cornerstone Pharmaceuticals CEO Dr. Robert Shorr please call (212) 843-8073 or email amazur@rubensteinpr.com.

###